Table AD3

Study 212

Mean (X) and Mean Change (∆) from Baseline in 21-item HAMD

LAST OBSERVATION CARRIED FORWARD ANALYSIS

Treatment

Groups

Treatment Week

Baseline

Wk 1

Wk 2

Wk 3

Wk 4

Wk 5

Wk 6

Wk 7

Wk 8

N

X

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

BUP SR 150 (L)

146

24.2

145

-4.3

146

-6.8

146

-8.5

146

-9.7

146

-10.3

146

-11.8

146

-12.2

146

-12.1

BUP SR 300 (II)

144

24.4

144

-3.1

144

-4.1

144

-6.9

144

-9.1

144

-9.7

144

-10.0

144

-10.8

144

-11.1

Placebo (P)

148

23.9

145

-3.4

148

-5.9

148

-8.0

148

-8.6

148

-9.6

148

-9.8

148

-9.9

148

-9.8

2-sided p-values for pairwise comparisons

L vs P

> 0.2

0.08

0.20

0.45

0.15

0.40

0.02

0.01

0.02

II vs P

> 0.1

0.52

0.004

0.14

0.33

0.91

0.86

0.36

0.16

OBSERVED CASES ANALYSIS

Treatment

Groups

Treatment Week

Baseline

Wk 1

Wk 2

Wk 3

Wk 4

Wk 5

Wk 6

Wk 7

Wk 8

N

X

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

BUP SR 150 (L)

146

24.2

145

-4.3

136

-6.9

133

-8.6

133

-10.1

122

-10.8

118

-12.8

117

-13.6

110

-13.7

BUP SR 300 (II)

144

24.4

144

-3.1

136

-4.3

131

-7.6

121

-10.6

111

-11.3

104

-11.8

104

-13.1

101

-13.4

Placebo (P)

148

23.9

145

-3.4

140

-6.0

132

-8.3

124

-9.2

117

-10.5

114

-11.2

107

-11.7

100

-11.6

2-sided p-values for pairwise comparisons

L vs P

> 0.2

.08

0.18

0l77

0.34

0.77

0.14

0.10

0.06

II vs P

> 0.1

0.52

0.006

0.29

0.09

0.49

0.66

0.22

0.10